Targeted therapy of BRAF V600E-mutant histiocytic sarcoma: A case report and review of the literature

Eur J Haematol. 2019 Oct;103(4):444-448. doi: 10.1111/ejh.13303. Epub 2019 Aug 23.

Authors

Benoît Branco¹, Thibault Comont², Loïc Ysebaert¹, Muriel Picard³, Camille Laurent⁴, Lucie Oberic¹

Affiliations

¹ Department of Haematology, IUCT-Oncopole, Toulouse, France.
² Department of Internal Medicine, IUCT-Oncopole, Toulouse, France.
³ Department of Intensive Care, IUCT-Oncopole, Toulouse, France.
⁴ Department of Anatomopathology, IUCT-Oncopole, Toulouse, France.

PMID: 31376203
DOI: 10.1111/ejh.13303

No abstract available

Publication types

Case Reports
Review

MeSH terms

Alleles*
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers
Biopsy
Female
Histiocytic Sarcoma / diagnosis
Histiocytic Sarcoma / drug therapy*
Histiocytic Sarcoma / genetics*
Humans
Mutation*
Positron Emission Tomography Computed Tomography
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use*
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
Proto-Oncogene Proteins B-raf / genetics*
Tomography, X-Ray Computed
Treatment Outcome
Young Adult

Substances

Antineoplastic Agents
Biomarkers
Protein Kinase Inhibitors
BRAF protein, human
Proto-Oncogene Proteins B-raf